Evotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
SynaptixBio Ltd and Evotec SE expand collaboration
Latest NewsEvotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
Von der Leyen: no mention of biotechnology
Latest NewsIn view of her confirmation as EU Commission President, biotech associations have reminded Ursula von der Leyen of her promise to strategically promote the sector with an EU Biotech Act 2025.
Scientists prevent transplant rejection
Latest NewsScientists at Hannover Medical School (MHH) have genetically engineered pig lungs in such a way that immunosuppressants could be reduced during transplants.
New Chief Scientific Officer
AppointmentsCambridge-based Mogrify Ltd announces the appointment of Dr. Jonathan Appleby as Chief Scientific Officer.
SOTIO partners with Biocytogen to expand ADC pipeline
Latest NewsCzech Sotio Biotech has inked an R&D and licence option agreement with Chinese antibody maker Biocytogen.
Draupnir Bio ApS raises further equity
Latest NewsTargeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.
CordenPharma invests €900m in peptide patform expansion
Latest NewsCordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.
Catalym raises US$150m
Latest NewsGerman cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies.
Sensorion achieves milestones in Phase II trial
Latest NewsFrench Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.
Rentschler doubles cGMP capacity
Latest NewsIn the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA.